MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-30-2026
Cytosorbents Corporation Retained Earnings 2011-2026 | CTSO
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Cytosorbents Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -312 M | -304 M | -283 M | -254 M | -221 M | -197 M | -189 M | -170 M | -152 M | -144 M | -133 M | -124 M | -106 M | -98.7 M | -92.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -92.6 M | -312 M | -185 M |
Quarterly Retained Earnings Cytosorbents Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -307 M | -304 M | -305 M | -304 M | -295 M | -293 M | -289 M | -283 M | -277 M | -267 M | -261 M | -254 M | -253 M | - | -230 M | -221 M | -212 M | -205 M | -201 M | -197 M | -197 M | -197 M | -197 M | -189 M | -189 M | -189 M | -189 M | -170 M | -170 M | -170 M | -170 M | -152 M | -152 M | -152 M | -152 M | -144 M | -144 M | -144 M | -144 M | -133 M | -133 M | -133 M | -133 M | -124 M | -124 M | -124 M | -124 M | -106 M | -106 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -106 M | -307 M | -196 M |
Retained Earnings of other stocks in the Medical devices industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
-633 M | $ 13.11 | 0.23 % | $ 1.77 B |  USA |
 |
BIOLASE
BIOL
|
-317 M | - | -13.19 % | $ 166 K | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
-533 M | - | - | $ 1.77 B | USA |
 |
Allied Healthcare Products
AHPI
|
-15.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
Eargo
EAR
|
-514 M | - | - | $ 10.2 M | USA |
 |
Apollo Endosurgery
APEN
|
-337 M | - | - | $ 475 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
-185 M | - | -5.86 % | $ 30.6 M | USA |
 |
Second Sight Medical Products
EYES
|
-149 M | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
21.2 M | $ 25.71 | 2.43 % | $ 217 M | USA |
 |
Avinger
AVGR
|
-421 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
-374 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-82.6 M | $ 3.32 | 0.3 % | $ 124 M |  France |
 |
Aziyo Biologics
AZYO
|
-176 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
-718 M | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
-581 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
-217 M | $ 11.18 | 8.12 % | $ 317 M | USA |
 |
Helius Medical Technologies
HSDT
|
-160 M | $ 2.04 | 3.03 % | $ 1.24 M | USA |
 |
Cardiovascular Systems
CSII
|
-424 M | - | 0.15 % | $ 844 M | USA |
 |
CryoLife, Inc.
CRY
|
20 M | - | -4.14 % | $ 702 M | USA |
 |
Inspire Medical Systems
INSP
|
-146 M | $ 56.14 | 5.11 % | $ 1.65 B | USA |
 |
Invacare Corporation
IVC
|
-78.4 M | - | - | $ 24.7 M | USA |
 |
Soliton, Inc.
SOLY
|
-70.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-56.2 M | - | -1.98 % | $ 98.3 M | USA |
 |
IRIDEX Corporation
IRIX
|
-92.4 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-119 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Dynatronics Corporation
DYNT
|
-40.5 M | - | 14.99 % | $ 929 K | USA |
 |
Misonix, Inc.
MSON
|
-39.3 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-395 M | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
-1.15 B | $ 60.1 | 2.0 % | $ 3.28 B |  Britain |
 |
OrthoPediatrics Corp.
KIDS
|
-275 M | $ 15.06 | 2.87 % | $ 353 M | USA |
 |
Butterfly Network
BFLY
|
-802 M | $ 4.79 | -2.64 % | $ 1.01 B | USA |
 |
Intersect ENT, Inc.
XENT
|
-303 M | - | - | $ 955 M | USA |
 |
GBS
GBS
|
-62.5 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
1.39 B | $ 90.18 | 2.72 % | $ 12.2 B | USA |
 |
Delcath Systems
DCTH
|
-529 M | $ 10.38 | 1.67 % | $ 372 M | USA |
 |
NanoVibronix
NAOV
|
-90.5 M | - | - | $ 1.08 M | USA |
 |
CONMED Corporation
CNMD
|
589 M | $ 36.66 | 1.95 % | $ 1.14 B | USA |
 |
Integer Holdings Corporation
ITGR
|
994 M | $ 88.51 | 5.78 % | $ 3.07 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
14.2 B | $ 83.5 | 2.81 % | $ 48.8 B | USA |
 |
LENSAR
LNSR
|
-178 M | $ 5.23 | -2.97 % | $ 62.5 M | USA |
 |
Pulmonx Corporation
LUNG
|
-522 M | $ 1.28 | 6.67 % | $ 52.1 M | USA |
 |
MiMedx Group
MDXG
|
-42.7 M | $ 3.36 | 8.91 % | $ 497 M | USA |
 |
Myomo
MYO
|
-119 M | $ 0.86 | 8.54 % | $ 36 M | USA |
 |
Cutera
CUTR
|
-303 M | - | -10.19 % | $ 1.99 M | USA |
 |
NuVasive
NUVA
|
86.1 M | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
-813 M | - | - | $ 217 M | USA |
 |
Natus Medical Incorporated
NTUS
|
84.5 M | - | 1.94 % | $ 1.05 B | USA |